Back to search

Aristotle University Of Thessaloniki (AUTH)

Εκτίμηση της προβλεπτικής και προγνωστικής σημασίας του mTOR (mammalian Target Of Rapamycin) σε ασθενείς με καρκίνο του μαστού

Abstract

dc:description

Scarce data exist on the prognostic/predictive value of p-Akt and p-mTOR protein expression in patients with high-risk early breast cancer. Formalin-fixed paraffin-embedded (FFPE) tumor tissue samples from 997 patients participating in two adjuvant chemotherapy phase III trials were assessed by immunohistochemistry (IHC) for EGFR, PTEN, p-Akt, p-mTOR and single nucleotide polymorphism (SNP) genotyping for PIK3CA mutations. These markers were correlated with selected patients and tumor characteristics, breast cancer immunohistochemical subtypes (classified by ER, PgR, HER2 and Ki67), disease-free survival (DFS) and overall survival (OS).concerning the results, p-mTOR protein expression was negatively associated with EGFR expression, but it was significantly positively associated with PTEN and p-Akt473 expression and presence of PIK3CA mutations. EGFR expression was significantly positively correlated with p-Akt473 and p-Akt308 protein expression and PIK3CA wild-type tumors. p-Akt308 expression was significantly positively associated with p-Akt473 expression. In univariate analysis EGFR (p=0.016), as well as the coexpression of EGFR and p-mTOR (hazard ratio [HR]=1.49, p=0.015) were associated with poorer OS although no association with DFS appeared. Among patients with p-Akt308 negative or low expressing tumors, those treated with hormonal therapy were associated with decreased risk for both relapse and death (HR=0.42, p=0.013 and HR=0.26, p<0.001, respectively). In multivariate analysis low levels of p-Akt308 and the coexpression of EGFR and p-mTOR retained their prognostic value. Low protein expression of p-AKkt308 was associated with improved DFS and OS among patients treated with hormonal therapy following adjuvant chemotherapy. Coexpression of EGFR and p-mTOR was associated with worse OS.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2013

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Lampaki, Sophia
  • Λαμπάκη, Σοφία

Subjects

dc:subject × 12

Rights

dc:rights
Statement dc:rights
  • BY_NC_ND
Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/36893

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Lampaki, Sophia; Λαμπάκη, Σοφία. Εκτίμηση της προβλεπτικής και προγνωστικής σημασίας του mTOR (mammalian Target Of Rapamycin) σε ασθενείς με καρκίνο του μαστού. Aristotle University Of Thessaloniki (AUTH), 2013. http://hdl.handle.net/10442/hedi/36893